55
Participants
Start Date
January 28, 2022
Primary Completion Date
October 28, 2022
Study Completion Date
October 28, 2022
Adjuvant
Adjuvant treatment with a standard NSCLC platin-based doublet, 4 cycle (21-day) regimen of the investigator's choice (Arm 1) or other adjuvant therapy (Arm 1a) which can include combination of chemotherapy and targeted therapy, immunotherapy or other.
Observation
All patients will be observed for progression free survival and overall survival to the end of study or death, whichever occurs first.
Penn Presbyterian Medical Center, Philadelphia
MedStar Washington Hospital Center, Washington D.C.
George Washington Medical Faculty Associates, Washington D.C.
Virginia Cancer Specialists, Fairfax
Mary Washington Hospital, Fredericksburg
West Virginia University Medicine, Morgantown
Piedmont Cancer Center, Atlanta
Jupiter Medical Center, Jupiter
Medical College of Wisconsin, Milwaukee
Northshore University Healthsystem, Evanston
The University of Kansas Hospital, Kansas City
Our Lady of the Lake Regional Medical Center, Baton Rouge
Texas Oncology-Wichita Falls Cancer Center, Wichita Falls
Texas Oncology-San Antonio Medical Center, San Antonio
Methodist Healthcare, San Antonio
City of Hope National Medical Center, Duarte
Providence Regional Medical Center Everett, Everett
Peace Health, Vancouver
Lead Sponsor
ClinLogix. LLC
INDUSTRY
Insight Molecular Diagnostics
INDUSTRY